Inventor

VOLKMER JENS-PETER

US30 patents

⚠️ This page may combine multiple inventors who share the name “VOLKMER JENS-PETER”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

VOLKMER JENS-PETER

UNIV LELAND STANFORD JUNIOR

Anti-SIRP-alpha antibodies and bispecific macrophage enhancing antibodies

Methods for achieving therapeutically effective doses of anti-CD47 agents for treating cancer

Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody

Methods for achieving therapeutically effective doses of anti-CD47 agents

Dosing parameters for CD47 targeting therapies to hematologic malignancies

Anti SIRP-α antibodies and bi-specific macrophage enhancing antibodies

Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody

Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRPα antibody therapy

Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody

Use of anti-CD47 agents to enhance immunization

Macrophages eat cancer cells using their own calreticulin as a guide

Treatment of cancer with dual targeting of CD47 and EGFR

SIRP-α agonist antibody

Dosing parameters for CD47 targeting therapies to hematologic malignancies

Methods for achieving therapeutically effective doses of anti-CD47 agents

Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRPalpha antibody therapy

Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer

Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer

Compositions for achieving therapeutically effective doses of anti-CD47 agents

Methods for treating myeloma by achieving therapeutically effective doses of anti-CD47 antibody

Dosing parameters for CD47 targeting therapies to hematologic malignancies

Use of anti-CD47 agents to enhance immunization

Use of TLR agonist and anti-CD47 agent to enhance phagocytosis of cancer cells

Treatment of cancer with dual targeting of CD47 and EGFR

Use of TLR agonist and anti-CD47 agent to enhance phagocytosis of cancer cells

Treatment of cancer with dual targeting of CD47 and EGFR

FORTY SEVEN INC

Anti-SIRP-alpha antibodies and related methods

Anti-SIRP-α antibodies and related methods

Anti-CD47 agent-based treatment of CD20-positive cancer

Anti-CD47 agent-based ovarian cancer therapy